In patients with ≥ 3 metastases (high disease burden; Fig. 2d), comparable results were observed (Verma S et al. Ribociclib + letrozole vs placebo + letrozole in postmenopausal women with HR+/HER2– advanced breast cancer and a high disease burden. The gene discussed is ERBB2; the disease is breast carcinoma.